Advertisement
CI vs ELV
Which Stock Would AI Choose? The Cigna Group (CI) vs. Elevance Health (ELV) Stock Comparison
Key Takeaways
- The Cigna Group (CI) and Elevance Health (ELV) are two of the largest U.S. managed-care and health-services companies, but their earnings mixes differ sharply: CI leans on its Evernorth pharmacy-benefit and specialty-pharmacy business, while ELV anchors on Blue Cross Blue Shield insurance plans plus its Carelon services arm.
- Recent relative performance has favored ELV, which is trading near a 52-week high after raising full-year guidance, whereas CI has lagged the sector during its portfolio reshaping and leadership transition.
- CI trades at a materially lower forward P/E (price-to-earnings ratio) than ELV, reflecting market caution around its PBM (pharmacy benefit manager) transition and ongoing regulatory scrutiny.
- Tickeron AI Verdict: ELV — the AI currently favors Elevance Health based on trend consistency, positive momentum, and a clearer near-term earnings catalyst path.
- For more detail on each company's developments and daily moves, explore CI Major News, CI Today's Price Move, ELV Major News, and ELV Today's Price Move.
- To see how automated strategies are positioning across the broader market, browse Trending AI Robots.
Introduction
The Cigna Group (CI) and Elevance Health (ELV) sit at the center of the U.S. healthcare economy, yet they generate profits in very different ways. CI has become a health-services heavyweight through Evernorth, its pharmacy benefit and specialty pharmacy arm, while ELV remains a leading insurer through its Blue Cross Blue Shield footprint, supplemented by the Carelon services platform. For traders and long-term investors weighing managed-care exposure, this stock comparison highlights a meaningful contrast: a value-priced name navigating a strategic transition versus a momentum-driven name delivering clearer earnings visibility. Understanding their relative performance, market positioning, and catalysts can help frame which profile better fits current market conditions.
CI Overview and Recent Performance
The Cigna Group (CI) is a diversified health company whose growth increasingly depends on Evernorth Health Services, which spans pharmacy benefit management, specialty pharmacy, and care services, alongside its Cigna Healthcare insurance operations. In recent weeks, CI has underperformed the broader healthcare sector, with shares trading in the high-$200s and down modestly year to date even as long-term returns remain positive.
Sentiment has been shaped by a series of strategic moves rather than a single catalyst. The company has outlined a multi-year, roughly $3 billion modernization and productivity program and a "Lead to One" vision targeting long-term adjusted EPS (earnings per share) growth, while also pursuing a CEO transition and portfolio reshaping, including plans to exit the individual exchange business and a review of its eviCore unit. Analysts have responded with mixed-to-neutral adjustments, citing multi-year uncertainty tied to the PBM (pharmacy benefit manager) transition and regulatory pressure on Express Scripts. Despite this, CI trades at a notably low forward P/E and maintains a steady dividend, framing it as a value-oriented story with execution risk.
ELV Overview and Recent Performance
Elevance Health (ELV) is one of the largest health insurers in the United States and the leading licensee of Blue Cross Blue Shield coverage, operating across commercial, Medicaid, Medicare Advantage, and individual plans. Its Carelon segment adds pharmacy, behavioral health, and care-delivery services that diversify revenue beyond premiums. In recent market activity, ELV has been a relative standout, climbing toward a 52-week high and outperforming many managed-care peers.
Momentum has been reinforced by a strong earnings update in which ELV reported adjusted EPS well above consensus expectations, raised its full-year adjusted EPS guidance to at least $29, and signaled confidence in at least 12% adjusted EPS growth in 2027 from a higher baseline. Improved Medicaid rate alignment, disciplined Medicare Advantage repositioning, and Carelon operating gains have supported the outlook, while the benefit expense ratio (the share of premiums spent on medical care) improved year over year. Headwinds remain, including declining medical membership and pressure on Health Benefits margins, but the market has rewarded the clearer earnings trajectory.
Trending AI Robots
Tickeron operates hundreds of AI-powered trading bots that collectively trade thousands of different tickers, each built with its own trading style, strategy, timeframe, performance record, and set of covered securities. Because market conditions shift constantly, not every bot is well suited to the current environment. That is why Tickeron curates a dedicated Trending AI Robots section, which highlights only the strategies demonstrating the strongest alignment with present-day market dynamics. The available bots span a wide range of approaches — from short-term momentum to longer-horizon trend following — allowing users to compare statistics, win rates, and drawdown profiles before following a strategy. Exploring this curated list can help traders identify automated signals currently gaining traction across the market.
Head-to-Head Comparison
The clearest contrast between CI and ELV lies in their business models. CI is now defined more by Evernorth's pharmacy and services scale than by traditional insurance, making its earnings sensitive to PBM regulation and client retention. ELV, by comparison, remains an insurance-first franchise whose Carelon unit provides incremental diversification. This difference flows through to valuation: CI trades at a lower forward P/E, while ELV commands a richer multiple justified by stronger near-term visibility.
On momentum, the two stocks have diverged. ELV's raised guidance and margin improvement have driven a re-rating toward 52-week highs, whereas CI's restructuring narrative and leadership change have kept sentiment cautious. Risk profiles also differ — CI faces regulatory and execution uncertainty around its PBM transition, while ELV contends with membership declines and ongoing Medicaid and Medicare Advantage cost pressures. In short, CI represents a potentially cheaper but less certain turnaround, while ELV offers more consistent trend strength at a premium valuation.
Tickeron AI Verdict
Based on observable factors including trend consistency, relative momentum, and catalyst visibility, Tickeron's AI would likely favor ELV over CI in the current environment. Elevance Health's combination of a rising price trend near 52-week highs, upwardly revised earnings guidance, and improving medical-cost ratios provides a more stable and confirmable signal set than Cigna's ongoing transition. While CI's lower valuation and dividend may appeal to value-focused investors, the AI's framework tends to weight trend persistence and near-term earnings clarity, both of which presently point toward ELV. This is a probabilistic assessment of current positioning rather than a definitive prediction of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CI is a Buy and ELV is a StrongBuy.
CI sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for CI moved above the 200-day moving average on October 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 31 of 51 cases where CI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 61%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on CI as a result. In 64 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.
CI moved above its 50-day moving average on October 07, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CI crossed bullishly above the 50-day moving average on October 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.
Following a +3.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where CI advanced for three days, in 224 of 355 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 169 of 276 cases where CI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The 10-day RSI Indicator for CI moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 21 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 58%.
The Moving Average Convergence Divergence Histogram (MACD) for CI turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 30 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
CI broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 33 (best 1 - 100 worst), indicating outstanding price growth. CI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.820) is normal, around the industry mean (3.520). P/E Ratio (12.077) is within average values for comparable stocks, (126.353). Projected Growth (PEG Ratio) (0.739) is also within normal values, averaging (0.786). CI has a moderately high Dividend Yield (0.021) as compared to the industry average of (0.009). P/S Ratio (0.264) is also within normal values, averaging (0.569).
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ELV in upward trend: 10-day moving average broke above 50-day moving average on October 13, 2026
The 10-day moving average for ELV crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 37 of 64 cases where ELV's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on ELV as a result. In 62 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
Following a +4.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where ELV advanced for three days, in 183 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 144 of 251 cases where ELV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Bearish Trend Analysis
The 10-day RSI Indicator for ELV moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 20 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Moving Average Convergence Divergence Histogram (MACD) for ELV turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 26 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 51%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ELV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
ELV broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 29 (best 1 - 100 worst), indicating outstanding price growth. ELV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.057) is normal, around the industry mean (3.520). P/E Ratio (18.775) is within average values for comparable stocks, (126.353). ELV's Projected Growth (PEG Ratio) (1.291) is slightly higher than the industry average of (0.786). Dividend Yield (0.016) settles around the average of (0.009) among similar stocks. P/S Ratio (0.453) is also within normal values, averaging (0.569).
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ELV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
CI | ELV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 52 Fair valued | 64 Fair valued | |
PROFIT vs RISK RATING 1..100 | 43 | 82 | |
SMR RATING 1..100 | 55 | 99 | |
PRICE GROWTH RATING 1..100 | 33 | 29 | |
P/E GROWTH RATING 1..100 | 37 | 9 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CI's Valuation (52) in the Managed Health Care industry is in the same range as ELV (64). This means that CI’s stock grew similarly to ELV’s over the last 12 months.
CI's Profit vs Risk Rating (43) in the Managed Health Care industry is somewhat better than the same rating for ELV (82). This means that CI’s stock grew somewhat faster than ELV’s over the last 12 months.
CI's SMR Rating (55) in the Managed Health Care industry is somewhat better than the same rating for ELV (99). This means that CI’s stock grew somewhat faster than ELV’s over the last 12 months.
ELV's Price Growth Rating (29) in the Managed Health Care industry is in the same range as CI (33). This means that ELV’s stock grew similarly to CI’s over the last 12 months.
ELV's P/E Growth Rating (9) in the Managed Health Care industry is in the same range as CI (37). This means that ELV’s stock grew similarly to CI’s over the last 12 months.
| CI | ELV | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 58% | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 61% | 2 days ago 58% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 63% |
| MACD ODDS (%) | 2 days ago 59% | 2 days ago 51% |
| TrendWeek ODDS (%) | 2 days ago 51% | 2 days ago 59% |
| TrendMonth ODDS (%) | 2 days ago 62% | 2 days ago 54% |
| Advances ODDS (%) | 3 days ago 63% | 9 days ago 57% |
| Declines ODDS (%) | 7 days ago 56% | 4 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 51% | 3 days ago 57% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 57% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CI’s FA Score shows that 1 FA rating(s) are green while ELV’s FA Score has 2 green FA rating(s).
- CI’s FA Score: 1 green, 4 red.
- ELV’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CI’s TA Score shows that 7 TA indicator(s) are bullish while ELV’s TA Score has 5 bullish TA indicator(s).
- CI’s TA Score: 7 bullish, 4 bearish.
- ELV’s TA Score: 5 bullish, 4 bearish.
Price Growth
CI (@Managed Health Care) experienced а -1.30% price change this week, while ELV (@Managed Health Care) price change was -1.08% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was +1.93%. For the same industry, the average monthly price growth was +4.07%, and the average quarterly price growth was +16.14%.
Reported Earning Dates
CI is expected to report earnings on Feb 04, 2027.
ELV is expected to report earnings on Jan 27, 2027.
Industries' Descriptions
@Managed Health Care (+1.93% weekly)Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
Advertisement
CI and
Correlation & Price change
A.I.dvisor indicates that over the last year, CI has been loosely correlated with ELV. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CI jumps, then ELV could also see price increases.
ELV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ELV has been closely correlated with UNH. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if ELV jumps, then UNH could also see price increases.